0% Annual Report Loaded

A research-driven pharmaceutical company, ZIM Laboratories Limited (ZIM labs) provides technology-based drug delivery solutions.

Established in 1989, we are engaged in developing, manufacturing and supply of differentiated generic products in oral solid dosages alongside offering pre-formulation intermediates (PFI) and finished formulations (FF) for certain key therapeutic segments across rest of the world (RoW) markets. We are now focused on expanding our offerings across two verticals - pharmaceuticals and nutraceuticals, to customers across the globe.

Our Vision

Our Values

Anwar Daud

Chairman & Managing Director

Dear Shareholders

I take great pleasure in presenting the annual report for the Financial Year 2022 (FY22). Hope that this finds you safe and in good health.

When the current financial year began, none of us expected that we would be confronted by a new and deadlier variant of Covid-19 in the first quarter, putting into greater stress the global supply chains and logistics and impacting business operations across industries.

As usual, it was the resilience and grit of our team that helped us overcome these challenges. It is an immense privilege to work with a team which has the passion and innovative spirit to overcome various obstacles faced in these extraordinary times to ensure our continued success.

We continue to make positive strides in operational excellence and process improvement to reduce costs while improving quality. We also progressed on developing and expanding our portfolio of specialty generics comingoff patent, in the near future, thus preparing products for submission in various markets.

Read More

ZIM’s Brands under Oral Thin Films

Some Pharmaceuticals under ZIM’s Brand

ZIMFIL- ODS 10

ZIMAGRA-ODS

VOMIBAR ODS 4

VANCAST ODS 10

FINEVIT D3

MONTEZIM-ODS 10